Table 3.
Sensitivity analysis
Increased odds of NCCRT (vs. esophagectomy) by unmeasured confounder (%) | Upper end of P value† for negative INB when WTP = US$150,000 |
---|---|
1.0 | 0.044 |
1.5 | 0.046 |
2.0 | 0.048 |
2.5 | 0.049 |
3.0 | 0.051 |
3.5 | 0.053 |
Rounded at the third decimal. ICER: incremental cost‐effectiveness ratio; INB, incremental net benefit; NCCRT, neoadjuvant concurrent chemoradiotherapy; WTP, willingness‐to‐pay (in United States dollars/life‐year).